- Home
- RCUS
as 12-20-2024 4:00pm EST
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | HAYWARD |
| Market Cap: | 1.4B | IPO Year: | 2018 |
| Target Price: | $34.50 | AVG Volume (30 days): | 755.7K |
| Analyst Decision: | Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.52 - $20.31 | Next Earning Date: | 11-06-2024 |
| Revenue: | $263,000,000 | Revenue Growth: | 119.17% |
| Revenue Growth (this year): | 127.13% | Revenue Growth (next year): | -18.38% |
Stock Insider Trading Activity of Arcus Biosciences Inc. (RCUS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Azoy Alexander | RCUS | Chief Accounting Officer | Dec 2 '24 | Sell | $15.32 | 201 | $3,079.32 | 19,070 |
Latest Arcus Biosciences Inc. News
RCUS Breaking Stock News: Dive into RCUS Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Shareholders in Arcus Biosciences (NYSE:RCUS) have lost 65%, as stock drops 9.9% this past week
Business Wire
2 days ago
Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Argus Research
4 days ago
RCUS: Lowering target price to $17.00
Argus Research
11 days ago
RCUS: Raising target price to $18.00
Business Wire
11 days ago
Arcus Biosciences Announces New Employment Inducement Grants
Argus Research
18 days ago
RCUS: What does Argus have to say about RCUS?
Business Wire
18 days ago
Arcus Biosciences Announces New Employment Inducement Grants
Argus Research
25 days ago
RCUS: Raising target price to $17.00
Compare RCUS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RCUS Arcus Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.